Extensive updates from broad and innovative portfolio also to be presented The 2023 American Academy of Dermatology (AAD) Annual Meeting will see the data premiere of the phase III OLYMPIA 2
Phase 2 results show a reduction in itch in patients with notalgia paresthetica, but 19% of patients discontinued the trial because of side effects compared with 6% in the placebo group.
The population-based cohort study, using electronic medical record data, also evaluated the association of inflammatory bowel disease with oral tetracyclines and with acne itself.
ASLAN Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.